Scoop: No­var­tis’ re­treat on CAR-T in­cludes ax­ing most of its se­nior ex­ecs on the team

No­var­tis’ plan to pull back on CAR-T in­cludes purg­ing most of the se­nior ex­ecs in­volved in the project, sig­nal­ing the phar­ma gi­ant’s R&D re­treat is more ex­ten­sive than the com­pa­ny has want­ed to ad­mit so far.

End­points News, which broke the sto­ry on No­var­tis’ sur­pris­ing R&D move, ini­tial­ly ob­tained the top frag­ment of an in­ter­nal cor­po­rate memo au­thored by Us­man “Oz” Azam at No­var­tis spelling out that the com­pa­ny is dis­solv­ing its cell and gene ther­a­py unit re­spon­si­ble for its pi­o­neer­ing work on CAR-T. Now we have the rest of it, and it in­cludes this on the team ex­ecs:

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER